Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy

Currently, there are two Food and Drug Administration (FDA)-approved drugs for androgen deprivation therapy (ADT) of metastatic castration-resistant prostate cancer (mCRPC) patients: abiraterone and enzalutamide. However, our understanding of the effect of these therapies on the immune system in mCR...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Sumanta K., Moreira, Dayson, Won, Haejung, White, Seok Woon, Duttagupta, Pryanka, Lucia, Marc, Jones, Jeremy, Hsu, JoAnn, Kortylewski, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515443/
https://www.ncbi.nlm.nih.gov/pubmed/31013891
http://dx.doi.org/10.3390/ijms20081831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515443/
https://www.ncbi.nlm.nih.gov/pubmed/31013891
http://dx.doi.org/10.3390/ijms20081831

Ejemplares similares